- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Alnylam Pharmaceuticals Inc. (ALNY)
by latest | most commented
-
Bio Medical Stock Sector is Where the Action Is
-
More on China Biotech Deals: M&A Numbers Misleading
-
Alnylam Wins Another China Patent for siRNA
-
FDA, Clinical Trial Calendar Updates: Theravance, Gilead, Teva, Alnylam, ReNeuron
-
Trading the Trials and FDA Decision Calendar
-
Cubist and Alnylam, An Odd Partnership
-
Can MicroRNA Reverse Heart Disease?
-
Four Biotechs at Attractive Entry Points
-
Even Fatter Yields for Pfizer; M&A Targets in the Sector
-
'When There's Blood in the Streets', Buy Biotech Stocks
-
Alnylam and RNAi: The Truth Hurts
-
Alnylam Pharmaceuticals: A Falling Star
-
My Model Biotech Picks: What's Hot and What's Not
-
Investing in miRNA: Beware the Hype, Follow the Money
-
Can Takeda (or Roche, or Merck, or...) Afford to Ignore RNAi?
-
Wednesday Options Outlook: AIG, LM, RL, XRAY, ALNY, EXPE, MAS, XLF, CSCO
-
Alnylam and Takeda Form Alliance In RNAi
-
Six Significant Gene Therapy Stocks
-
Isis Pharmaceuticals Panic Overdone
-
Rosetta Genomics: Mining Genes From Junk (Part II)
-
China Biotech in Review: Approvals, Deals and Company News
-
Alnylam Signs First Transaction with China Biotech on RNAi Research Products
-
Alnylam Stakes Claim to 1st Human Demo of Activity for RNAi Therapy
-
2007 Biotech Performance Review
-
PBE: Large Biotech Meets Small Biotech
-
RNAi: Seeking a Cure at the Flick of a Switch
-
RNA Interference Stocks: Invest At Your Own Risk
-
Gaming Rules For Trading Biotech Stocks
-
Alnylam Pharmaceuticals Soars on Roche Holding Collaboration
-
Biotech Day In Review: CuraGen Gets $155 Million For Gene Sequence Division
-
Biotech Day In Review: Amgen Hit with SEC Investigation
-
Eye on Alnylam: Silencing the Gene
-
Best Stem Cell Plays: Osiris and Aastrom
-
Biotech Stocks Review: Amphora Sells Oncology Program to Genentech
-
Alnylam, CytRx Gain by Moving into RNAi
-
Biotech IPO: Highlights from Rosetta Genomics' F1 Filing